Zantac Eliminated From Shelves Due To Carcinogen Issues

FDA investigates Zantac due to possible low-level of carcinogen included in the active ingredients. // Photo by CNN
The U.S. Food and Drug Administration (FDA) alerted that Zantac and other ranitidine products, which is a popular heartburn treatment, may have low-level of N-nitrosodimethylamine (NDMA), a possible human carcinogen.

As stated on the FDA’s website, NDMA is classified as “a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.”

During the preliminary tests, the drug exceeds the amount and level of contaminants.

Zantac and Topcare ranitidine products are being pulled from the market with massive caution after are being pulled from the market with massive caution after the industry-wide warning.

“Zantac brand products and CVS brand ranitidine products have not been recalled, and the FDA is not recommending that patients stop taking ranitidine at this time,” CVS said in a statement.

According to CVS Pharmacies, they have suspended sales of over-the-counter heartburn medicines while FDA is still reviewing the possible active ingredients in Zantac. The medicines’ suppliers also temporarily halted distributions of them in U.S and Canada markets.

Consumers can see a full list of the recalled ranitidine tablets on the FDA’s website.

Leave a Reply

Your email address will not be published. Required fields are marked *